In solid tumours, initiation, progression and therapeutic response are strongly influenced by paracellular signalling between cancer cells and cells in the tumour microenvironment (TME), such as immune cells, endothelial cells and their precursors and fibroblasts. This signalling provides resistance to environmental stresses or cancer therapies that induce cell death and supports invasion and metastasis.
The primary monocilium, expressed on almost all non-haematological cell types in the body, is emerging as a mediator of paracellular signals that control cancer growth and therapeutic responses. Vertebrate monocilia, typically referred to as primary cilia, have structural features in common with the motile flagella of simple eukaryotes such as Chlamydomonas and have been studied for over 60 years. Cilia protrude from the cell surface into the extracellular space and function as spatially restricted hubs, displaying receptors through which cues from soluble ligands or from ligands tethered to the extracellular matrix (ECM) can be received. Although cilia play important roles in tissue patterning in development and inherited mutations affecting core ciliary components lead to a group of syndromes known as ciliopathies 1 (Box 1), until recently, the role of cilia in cancer has not been generally appreciated. encompassing a microtubule-based core (the axoneme) anchored by the basal body (a modified centriolar structure that has undergone previous mitotic division) ( Fig. 1) . Structures associated with a transition zone located near the base of the cilium, including a ciliary gate, help maintain a higher concentration of specific proteins and lipids in cilia (reF. 8 and references therein).
Ciliary protrusion-resorption cycles, length control and cell cycle. The formation of the primary cilium is directly linked to control of the cell cycle [9] [10] [11] [12] [13] and occurs postmitotically in the G0 or early G1 phase, beginning with axoneme protrusion from the basal body. The cilium typically (although not invariably) persists through G1 but is resorbed before cells enter mitosis (Fig. 2) . The timing of resorption differs between different cell lineages, most commonly occurring in S or G2 phase. Following resorption, the centriole is released from the former ciliary basal body and undergoes a differentiation process to serve as a microtubule-organizing centre and support mitosis. When the cells become quiescent, the basal body migrates back to the membrane, and cilium formation recommences. The protrusion and resorption processes, and the trafficking of some ciliary signalling proteins, depend on regulation of the intraflagellar transport (IFT) machinery (Fig. 1) , which is supported by action of the BBSome (containing several Bardet-Biedl syndrome (BBS) proteins), Meckel syndrome (MKS) and nephronophthisis (NPHP) complexes, as well as by other proteins 14, 15 . Definition of the signalling cues governing the physical machinery for assembly and disassembly has been a topic of great interest ( Fig. 2 ; reviewed in reFs 11, 13, 16, 17 ). Aurora kinase A (AURKA), Polo-like kinase 1 (PLK1) and NIMArelated kinases (NEK), which are regulators of the cell cycle, have emerged as crucial regulators of cilia disassembly. Suggestively, altered expression and/or activity of some of these proteins are directly linked to cell transformation 18, 19 . In addition to controlling protrusion and resorption, some of these signalling pathways modulate ciliary length 17 , an important rheostat for cilia-based signalling receptors.
In the past decade, accumulating data have established direct links between signalling processes mediated through ciliary receptors, signalling processes that regulate ciliary formation and function, and signalling processes that regulate tumour growth and response to treatment. These links impact core cancer signalling pathways, including the Hedgehog (HH), WNT and platelet-derived growth factor (PDGF) cascades; the proteasome; mitotic regulatory kinases; and the DNA damage response. In this Opinion, we highlight important new findings about the role of cilia in cancer and suggest directions for future research.
Essential properties of cilia Our current understanding of mammalian cilia is to a large extent based on insights from foundational research into the flagellum in the green algae Chlamydomonas [2] [3] [4] [5] [6] [7] , the description of which is beyond the scope of this Opinion. We also note that the biology of the primary monocilium differs in some important regards from that in specialized multiciliated cells (Box 2), which we do not cover here.
Primary cilia localize to the surface of the majority of cells in most adult vertebrate cell types (with the notable exception of haematopoietic cells). The ciliary structure is a compartmentalized membrane Abstract | Although tumours initiate from oncogenic changes in a cancer cell, subsequent tumour progression and therapeutic response depend on interactions between the cancer cells and the tumour microenvironment (TME). The primary monocilium, or cilium, provides a spatially localized platform for signalling by Hedgehog, Notch, WNT and some receptor tyrosine kinase pathways and mechanosensation. Changes in ciliation of cancer cells and/or cells of the TME during tumour development enforce asymmetric intercellular signalling in the TME. Growing evidence indicates that some oncogenic signalling pathways as well as some targeted anticancer therapies induce ciliation, while others repress it. The links between the genomic profile of cancer cells, drug treatment and ciliary signalling in the TME likely affect tumour growth and therapeutic response.
Signalling influenced by ciliation Several signalling pathways important for paracellular communication between cancer cells and cells in the TME have been associated with the primary cilium, of which HH, Notch, WNT and PDGF signalling are some of the best characterized 20, 21 (Fig. 3 ).
Because this field is only emerging, for some of these ciliary signalling pathways, their relevance to tumour pathogenesis has been explored in only a limited number of tumour types: however, relevance has been demonstrated for all systems noted below in at least some tumour types.
Hedgehog. The HH signalling system 22 ( Fig. 3a) promotes tumour growth by serving as an oncogenic driver conditioning the TME in several tumour types. The three HH family members in mammals include Sonic HH (SHH), Indian HH (IHH) and Desert HH (DHH). SHH has been most studied. HH proteins are secreted by epithelial or tumour cells and bind to the receptor Patched (PTCH1), which is localized to the ciliary membrane of either the HH-secreting cell or neighbouring cells, which can be either additional epithelial and/or tumour cells or non-transformed stromal cells. In the absence of HH binding, PTCH1 provides repressive signals that sequester a second protein, Smoothened (SMO), in intracellular vesicles outside the cilium 22, 23 . HH binding to PTCH1 causes PTCH1 to be trafficked out of cilia, allowing SMO to translocate into the cilia where it activates a transcriptional programme dependent on zinc finger protein GLI effectors 24 . Additional cellular proteins can modulate this signalling: for example, G protein-coupled receptor 161 (GPR161) has recently been defined as an HH regulator with cancer relevance (Supplementary Table 1 ). Activated GLI proteins move to the nucleus, where they bind and activate transcription of a suite of genes that control processes relevant to tumour growth and treatment resistance. These genes include cyclin D1 (CCND1) and MYC (controlling proliferation), zincfinger protein SNAI1 (controlling epithelialmesenchymal transition (EMT)), BCL2 (controlling survival), transcription factor SOX2 and homeobox protein NANOG (controlling stem cell identity), and angiopoietin 1 (ANGPT1) and ANGPT2 (controlling angiogenesis).
Notch.
The transmembrane Notch proteins (NOTCH1-NOTCH4) regulate cell fate determination and tissue homeostasis (Fig. 3b) . In cancer, abnormal activation of Notch proteins in lung, breast and other tumour types enhances stem cell characteristics, promotes invasion and metastasis and supports angiogenesis, in part via interactions with receptor tyrosine-protein kinase ERBB2 and vascular endothelial growth factor (VEGF) signalling cascades 25, 26 . Notch pathway activation (for example, in embryonal development) requires cleavage of ligand-bound, activated Notch by the γ-secretase complex, which is localized proximal to the basal body, leading to release of the Notch intracellular domain (NICD). NICD translocates to the nucleus where it forms a complex with the transcription factor CSL (also known as RBPJ or CBF1 in mammals) and induces MYC, CCND3, HES family bHLH transcription factor 1 (HES1) and other genes. A study of skin development has shown that knockdown of IFT transport proteins causes defects in Notch signalling and impairs progenitor cell differentiation 27 . Further, during epidermal and neural differentiation, Notch signalling primes progenitor cells to respond to SHH by lengthening cilia and regulating localization of SMO and PTCH1 at cilia [27] [28] [29] .
WNT. A large group of secreted WNT ligands influence the balance between cellular differentiation, polarity controls and proliferation to regulate tissue homeostasis 30 . Altered WNT signalling (Fig. 3c) contributes to the loss of cell polarity that is associated with increased proliferation in numerous epithelial cancers (for example, reF.
31
) Canonical WNT signalling depends on activation of a β-catenin effector. Non-canonical WNT signalling involves regulation of planar cell polarity (PCP) effectors, and proteins such as phospholipase C (PLC), that regulate calcium responses 30 . Importantly, in studies of embryonal development performed in multiple vertebrate species and cell types, primary cilia have been reported to act as a switch between canonical and noncanonical WNT signalling, which induces distinct sets of genes influencing cell polarity and cell growth, and disruption of ciliogenesis caused by mutations affecting ciliary transport restricts the canonical WNT pathway 32, 33 (although at least one study of embryonal development has challenged these findings, implying cell type specificity 34 ). Studies in numerous vertebrate cell types, and in zebrafish and Xenopus development, have indicated that the ciliary protein inversin (INVS) regulates the expression and localization of the key WNT effector Dishevelled segment polarity protein 1 (DVL1), targeting it for degradation and thereby controlling pathway outputs 33 . On the basis of studies in transgenic mice, zebrafish embryos and human cell lines aimed at gaining insight into normal development and differentiation, BBS proteins interact genetically with proteins essential for PCP signalling, and BBS mutations share phenotypes with mutations in proteins involved in PCP 35 . Subsequently, in zebrafish embryos, Wnt11 and Wnt5b were shown to
Box 1 | Inherited defects in ciliary genes lead to ciliopathies
Structural integrity and regulation of the primary cilium are essential from the earliest stages of embryogenesis 22 for pattern formation and development of many organs. Distribution of cilia is lineage-dependent and stable throughout much of gestation 52 , which specifies the location and types of cells that can respond to ligands with cilia-localized receptors for autocrine, paracrine and mechanical signals. These include receptors of the Hedgehog (HH) family, which are essential for the development of nearly every organ in mammals 22, 155 ; platelet-derived growth factor receptor-α (PDGFRα), which contributes to skeletal formation and craniofacial development 156 ; and polycystin 1 (PKD1) and PKD2, which are essential for development of the kidney and the lymphatic system 157 . Because of these critical functions, inherited mutations in the genes encoding ciliary proteins or signalling proteins with obligate action on cilia result in serious developmental disorders called ciliopathies 1 . over 35 different kinds of ciliopathies and 187 established and 241 candidate ciliopathy-associated proteins have been reported 1 . Affected organs and processes include the brain (holoprosencephaly, juvenile myoclonic epilepsy and medulloblastoma), heart (congenital heart defects), kidney (nephronophthisis and autosomal dominant and autosomal recessive polycystic kidney disease), liver (liver fibrosis), eyes (leber congenital amaurosis, cone-rod dystrophy and retinitis pigmentosa), nose (anosmia and isolated congenital), ears (hearing loss), face (facial anomalies), reproductive system (hypogonadism, genital anomalies and infertility), skeleton (ellis-van Creveld syndrome, Jeune asphyxiating thoracic dystrophy, orofaciodigital syndrome and short-rib thoracic dysplasia), energy homeostasis (obesity) and organ placement (situs inversus and heterotaxy). Some syndromes have complex effects on multiple systems (as in Bardet-Biedl syndrome, Cole-Carpenter syndrome, hydrolethalus syndrome, Joubert syndrome, meckel-Gruber syndrome, mental retardation, truncal obesity, retinal dystrophy and micropenis (moRm) syndrome, Senior-løken syndrome, Birt-Hogg-Dubé syndrome and others) [158] [159] [160] .
functionally interact with Bbs1, Bbs4 and Bbs6 (also known as Mkks), and depletion of these BBS proteins reduced degradation and increased Wnt signalling through a β-catenin canonical effector 36 .
Receptor tyrosine kinases and other membrane-associated kinases. Elevated expression or activity of receptor tyrosine kinases (RTKs) is one of the most common oncogenic driver mechanisms. While RTKs are typically thought of as acting from microdomains on the plasma membrane, a growing body of work demonstrates that ciliary pools of RTKs exist and may have specialized regulatory function. One of the earliest examples of a ciliary RTK function was the demonstration that PDGF receptor-α PDGFRα localized to primary cilia in mammalian fibroblasts (Fig. 3d) , that the cilia were required for fibroblasts to respond to the PDGF-AA ligand and that PDGF-AA activated MEK1 and/or MEK2 specifically at the basal body, resulting in transcription of cancer-relevant pro-proliferative genes including STAT, FOS and JUN
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. Unciliated fibroblasts are unable to respond to PDGFRα-dependent chemotaxis signals [38] [39] [40] and have elevated signalling of the cancerrelevant RTK effector mTOR 41 . PDGFRα is expressed on cilia on numerous cell types, including fibroblasts, ovarian surface epithelial cells, neuroblasts and others 42 . Various studies have shown that cancerrelevant RTKs including insulin-like growth factor 1 receptor (IGF1R), epidermal growth factor (EGF) receptor (EGFR), angiopoietin receptors (TIE1 and TIE2 (also known as TEK)), fibroblast growth factor receptor (FGFR) and recepteur d' origine nantais (RON; also known as MST1R) are located within or proximal to primary cilia in nonmalignant cells of various tissues 42 . For some of these RTKs, differences in activation capacity based on ciliary localization have been reported: for instance, in adipocyte differentiation, ciliary IGF1R is more sensitive to insulin than the receptor found on the plasma membrane 43 . In addition to RTKs, the function of the transforming growth factor-β (TGFβ) serine/threonine kinase receptor, an important mediator of EMT, has been linked to the primary cilium in some cell types, such as human and murine fibroblasts. Cell surface expression of TGFβ receptors is regulated in part by clathrin-dependent endocytosis, a process organized at the ciliary pocket, and there is evidence for a localized pool of cilia-associated TGFβ receptors, with genetic loss of cilia reducing TGFβ-mediated signalling in some systems, such as human fibroblasts 44 .
Other ciliary signalling systems. Cilia are also involved in transmitting cues through mechanosensation, directly through interactions with tethered structures or indirectly through bending induced by nodal flow, shear stress forces or changes in osmolarity in cilia interacting with fluids in luminal space.
In development and in tumours, growth of cilia-expressing cells is conditioned by the mechanical stiffness of the microenvironment, which reflects the composition of ECM produced by both the ciliated cells and the stroma 45 . Part of this response reflects physical changes in the ECM architecture; for example, one study showed that growing human mesenchymal stem cells on micropatterned grooves was sufficient to lengthen cilia and alter WNT-β-catenin signalling in a process dependent on reorganization of intracellular actin-myosin signalling 46 . Integrins and neural/glial antigen 2 (NG2; also known as RNF5) proteoglycans displayed on cilia in murine chondrocytes mediate interactions with fibronectin and other specific ECM component proteins, with integrin activity regulating a cell attachment signalling cascade through interactions with the integrin effectors SRC and focal adhesion kinase (FAK; also known as PTK) and through the triggering of calcium signalling 47, 48 . Defects in this signalling process can lead to fibrosis, a common element in the TME that promotes cancer progression 45 . A growing number of G protein-coupled receptors (GPCRs) have been found to localize to the cilia on many types of human cells 49 . Importantly, these GPCRs include receptors for a wide variety of signals relevant to energy homeostasis. Defects in cilia manifested through dysfunction of these signalling systems have been strongly associated with obesity, a predisposing condition for cancer 50, 51 .
Cilia, cancer pathogenesis and therapy As discussed below, ciliation is not ubiquitous in all cells in mature adults. This fact, coupled with the fact that cilia undergo resorption-protrusion cycles linked to cell cycle and external stressors, has important consequences for the role of these organelles in the context of cancer and cancer-directed therapies. A minimal implication of this cycling process is that cellular capacity to respond to ligands for, or drugs targeting, ciliary receptors is heterogeneous across organ systems and cell types. An intriguing implication is that a subset of oncogenic drivers, through under-appreciated effects on control of ciliation, may lead to complex, cell type-specific responses to therapies targeting signalling systems with a ciliary component. A growing body of evidence supports these possibilities.
Cell lineage and transformationdependent ciliation. From the earliest stages of embryogenesis, lineage-specific differences in cell ciliation result in functional differences in response to HH
Box 2 | The special case of multiciliated cells
Specific cell types within vertebrates are multiciliated (~200 to 300 cilia per cell) rather than expressing primary monocilia. multiciliated cells (mCCs) are found in the ventricles of the brain and spinal cord (the ependymal cells), with other mCCs in airway epithelia (for example, nasal, tracheal and lung) and in the fallopian tubes. They differ from monociliated cells in several key features (reviewed in reF.
161
). First, these cilia are motile and are based on sliding of intraflagellar dynein arms on a 9 + 2 microtubule structure, with regulated movements vital for movement of fluids or (in the fallopian tube) transit of the ovum. Second, these cells are postmitotic and terminally differentiated, with multiciliation arising from a regulated over-replication of basal bodies. Third, mCCs are similar to monocilia in relying on intraflagellar transport and Bardet-Biedl syndrome (BBS) proteins for ciliogenesis and function, they typically do not resorb and their formation is regulated by very different cues than those in monocilia. It is plausible that defects in multicilia may also contribute to cancer, although by less direct means. As one example, ciliary beating by the multiciliated epithelium provides a first line of defence to cleanse the airways of inhaled debris, pathogens and other inflammatory stimuli and antigens. Genetic or induced changes affecting length, structure, orientation, percentage of ciliated cells, ciliary beat frequency and pattern and the susceptibility of the cilia to endogenous and exogenous stimuli can contribute to lung disease 162 . The most common inherited airway cilia dysfunctions include primary cilia dyskinesia and cystic fibrosis, with mutations often leading to defects in cilia or partial structural abnormalities in cilia 163, 164 . Airway cilia functions can also be influenced by environmental stressors such as pneumonia, rhinitis and asthma, pollutants, smoking, oxidative stress and abnormal mucus production 162 . Structural or functional abnormalities in airway cilia are hence associated with chronic obstructive pulmonary disease and interstitial lung disease, conditions that influence lung cancer risk.
and other cues 52 . In mature organisms, ciliation differences persist in distinct tissues, and oncogenic transformation influences ciliation status in distinct ways.
For example, although lymphoid cells utilize some components of the IFT machinery in formation of the immune synapse, these cells lack cilia 53, 54 . By contrast, in mouse mammary tissue, cilia are present on luminal epithelial, myoepithelial and stromal cells during branching morphogenesis in development but subsequently are lost from cells of the luminal epithelia. Mutations in IFT proteins compromise mammary branching, a process that is linked to increased canonical WNT and decreased HH signalling 55 and likely reflects defects in paracellular signalling from SHH-expressing luminal cells to ciliated basal cells 56 . In humans, the percentage of ciliated mammary cells is reduced early in tumour formation, in pre-malignant lesions and in invasive breast cancers 57, 58 . This is associated with low expression of ciliary structural proteins, including those that are required for the IFT and BBSome complexes 58 . Ciliation is also reduced, although to a lesser extent, in the surrounding stromal cells in both premalignant and invasive cancers. Inhibition of ciliogenesis in the polyoma middle T (PyMT) mouse model of breast cancer by deletion of Ift88 in the tumour cells caused earlier tumour formation, faster tumour growth, higher-grade tumours and increased metastasis 59 , coupled with elevated HH pathway activity.
As another example, in the pancreas, cancer formation commonly goes through set stages in which ductal acini typically convert through pancreatic intraepithelial neoplasia precursor stages 1-3 to overt pancreatic ductal adenocarcinomas (PDACs). Although normal pancreatic ductal epithelia, islet cells and centroacinar cells are highly ciliated, the number of cilia is sharply reduced during formation of PDACs, from the earliest precursor stages 60 , and in cases of the pre-neoplastic condition of pancreatitis 61 . Human PDACs have high levels of intratumoural heterogeneity, with some cancer cells more differentiated and some less so; a study of clinical outcomes showed that residual ciliation of cancer cells segregated to the well-differentiated areas (Fig. 4a) and that a higher level of cancer cell ciliation was prognostic of improved overall survival 62 . In mouse models, induced loss of ciliation by deletion of IFT components (Ift88 and kinesin family member 3a (Kif3a)) in the pancreatic epithelium, or constitutive loss of these components, caused abnormalities, including ductal metaplasia and dilatation, fibrosis, abnormal ductal morphology and lipomatosis 63, 64 . Similarly, cancer cell ciliary loss in prostate cancer is associated with elevated WNT-β-catenin activity, loss of tissue homeostasis and increased malignant characteristics 65 ; in ovarian cancer, it is associated with defects in HH and PDGFRα signalling 66 and is similarly associated with aggressive tumour growth in chondrosarcomas 67 and in other cancer types 68 . Importantly, some cancers depend on retention of ciliation rather than loss of ciliation. Two well-studied examples are medulloblastoma (Fig. 4b) and basal cell carcinoma (BCC), both of which depend on activation of the HH signalling pathway within cancer cells. Intriguingly, although constitutive HH signalling is required in these tumours, this can be achieved either through mutational activation of ciliary proteins that act upstream, such as SMO or PTCH1, or downstream, such as GLI2, in the cascade. Primary cilia have a tumourpromoting effect in medulloblastoma and BCC if the tumour-inducing event is oncogenic mutation of Smo but have a tumour-inhibitory effect if the tumourinducing event is mutational activation of Gli2, as first shown in mice 69, 70 . These seemingly paradoxical effects are consistent with a role for cilia as a platform for both the activation and the repression of the HH signalling pathway 70 . Here, activation of HH signalling is mediated through SMOdependent induction of protein kinase A (PKA) phosphorylation of GLI2, which switches GLI2 from a repressive to an active form, leading to induction of target gene transcription 70, 71 . Hence, if Ptch1 or Smo are mutationally activated, cilia are required for transmission of downstream signalling. However, when Gli2 is mutationally activated, the reduction of cilia number (by genetic deletion of Kif3a, a factor required for cilia assembly) does not affect skin tumorigenesis 70 .
Ciliation in the tumour microenvironment.
Among the cells of the TME, infiltrating lymphocytes and myeloid cells are generally non-ciliated, whereas fibroblasts and endothelial cells are more likely to be ciliated than cancer cells (Fig. 4a,b) . Because many important signalling systems are localized to cilia, this asymmetry between cancer and non-cancer cells impacts paracellular signalling in the TME.
Increased SHH secretion by cancer cells in pancreatic cancers and other cancers of the digestive tract, including The axoneme is typically constructed from nine parallel microtubule doublets protruding from the mother centriole (also known as the basal body), which anchors the primary cilium within the plasma membrane. Y-shaped axoneme-to-membrane connectors, known as the transition zone (TZ) ultrastructure, separate soluble and membrane-associated ciliary proteins from proteins in the cytoplasm and plasma membrane and function as a 'ciliary gate', limiting the entry of some signalling proteins into cilia 165 . This gate depends on the actions of proteins from two complexes or signalling modules, known as the Meckel syndrome (MKS) and nephronophthisis (NPHP) complexes, to ensure appropriate TZ formation and gate function. For many proteins, transport into and within the cilium depends on active transport by the intraflagellar transport (IFT) machinery (a complex of proteins); for others, entry occurs by passive diffusion. Protein-bearing vesicles emerging from the Golgi or sorting endosomes are sorted towards the periciliary membrane and captured by proteins of the IFT machinery. The core elements of the IFT machinery are two subcomplexes, A and B, linked to a BBSome complex (containing several BardetBiedl syndrome (BBS) proteins) bearing cargo. Association of the IFT complexes with kinesin 2 mediates trafficking to the ciliary tip (anterograde transport), and release of protein cargo occurs during progression towards the ciliary tip. At the tip, exchange of motors occurs, with dynein 2 mediating return trafficking of the IFT particles and the BBSome complex to the ciliary base (retrograde transport), allowing recycling and ciliary export.
oesophageal, stomach and biliary tract (but excluding colorectal), is required for tumour growth 72, 73 . In pancreatic cancer, SHH in conjunction with other factors (such as TGFβ) induces the recipient pancreatic stellate cells in the TME to undergo a desmoplastic reaction that in turn drives aggressive phenotypes 74 . An extensive proteomic analysis dissecting this interaction demonstrated that PDAC secretion of SHH caused recipient pancreatic stellate cells to transcribe a suite of genes required for desmoplastic ECM production and to excrete the growth factors IGF1 and growth arrest-specific protein 6 (GAS6). These growth factors reciprocally stimulated the IGF1R-insulin receptor substrate 1 (IRS1) and AXL oncogene-tyrosine-protein kinase receptor TYRO3 axes on PDAC cells, supporting the activation of over 90% of the measurable cancer cell phosphoproteome 75 . ). Ciliogenesis depends on activity of the GTPases RAS-related protein RAB8 and RAB11; RAB3A-interacting protein (RAB3IP; also known as RABIN8), a GDP-GTP exchange factor for RAB8; and GTPase tethering complexes (TRAPPII) for the introduction of ciliary vesicles into the elongating cilium 14 . The distal appendage protein CEP19 is recruited to the mother centriole by the fibroblast growth factor receptor 1 oncogene partner (FOP1)-CEP350 complex to capture GTP-bound RAB-like protein 2B (RABL2B), which in turn mediates ciliary entrance of intraflagellar transport (IFT) B complexes in the early steps of protrusion (reFs 168, 169 and others). Some of the noted proteins are implicated in cancer pathogenesis (Supplementary Table 1 ). In disassembly 11, 13 , activation of Aurora kinase A (AURKA), Polo-like kinase 1 (PLK1) and NIMA-related kinase (NEK) families serves as a proximal signal at the basal body , triggering resorption. This signalling is dependent on upstream cues provided by activators including neural precursor cell expressed, developmentally down-regulated protein 9 (NEDD9), pitchfork (PIFO), histone deacetylase 6 (HDAC6) and other proteins. Transient accumulation of calcium at the ciliary basal body stimulates calmodulin (CaM) binding and activation of AURKA , supporting ciliary disassembly 170 . PLK1 phosphorylation of nephrocystin 1 (NPHP1) in the transition zone 120 and association with Dishevelled segment polarity protein 2 (DVL2) activates NEDD9-AURKA at the basal body 121 and promotes ciliary disassembly 121 . In parallel, the interactions of NEK2 with the kinesin family member 24 (KIF24) at the basal body and phosphorylation of dynein light chain Tctex type 1 (DYNLT1) at the ciliary transition zone also promote the disassembly process and S phase entry (reviewed in reF.
11 ). EHD1, EH domain-containing protein 1; GSK3β, glycogen synthase 3β; KIF2A , kinesinlike protein KIF2A ; SNAP29, synaptosomal-associated protein 29; pVHL , phosphorylated von Hippel-Lindau disease tumour suppressor protein. • ↑ CCND and/or CCNE • ↑ CCND and/or CCNE 171 . When HH is bound, PTCH1 and GPR161 are removed, and SMO translocates into the cilia, where it activates zinc-finger protein GLI1 and/or GLI2 172 , which trigger transcription of GLI-targeted genes. b | Notch pathway signalling requires ligand binding to the Notch receptor (NOTCH1-NOTCH4), cleavage of the Notch receptor, release of Notch intracellular domain (NICD) and complex formation with the transcription factor CSL (also known as RBPJ or CBF1 in mammals) in the nucleus, followed by transcriptional activation of Notch target genes. c | Canonical WNT signalling is shown right of the dotted line and non-canonical WNT signalling is shown left of the dotted line. In the absence of WNT ligand, the β-catenin destruction complex (DC), composed of AXIN, adenomatous polyposis coli (APC), protein phosphatase 2 (PP2A), glycogen synthase 3β (GSK3β) and casein kinase I isoform-α (CK1α), efficiently promotes β-catenin degradation by the proteasome. In the canonical WNT pathway , a WNT ligand (for example, WNT1-WNT3, WNT8A , WNT8B, WNT10A or WNT10B) binds to Frizzled (FZ) and low-density lipoprotein receptor-related protein 5 (LRP5) or LRP6, which recruit Dishevelled segment polarity protein (DVL) and the DC. This association inactivates the DC, allowing β-catenin to translocate to the nucleus to induce transcription of target genes (indicated by red arrows). The ciliary protein inversin (INVS) regulates proteasomal degradation of DVL and hence influences accumulation of β-catenin 28 . In the non-canonical pathway , distinct WNT ligands (for example, WNT4, WNT5A , WNT5B, WNT6, WNT7A , WNT7B and WNT11) bind FZ, but INVS here acts to promote DVL recruitment and activation of JUN N-terminal kinase (JNK) and RHOA , regulating planar cell polarity (PCP) 28 (indicated by blue arrows). d | The PDGF-AA (a homodimer of the PDGF-A chain) ligand binds to cilia-localized PDGFRα. Downstream activation of the MEK1 and/or MEK2 and AKT effectors is mediated proximal to the basal body and results in transcription of pro-proliferative genes, including STAT, FOS and JUN. CCND3, cyclin D3; DAAM1, Dishevelled-associated activator of morphogenesis 1; DELTA , Delta-like protein; GLI2
A and GLI3
A , activated GLI2 and GLI3; HES1, HES family bHLH transcription factor 1; PLCB1, phospholipase Cβ1; PTK7 , protein-tyrosine kinase 7; SHH, Sonic HH; SUFU, suppressor of fused homologue.
This result implied the profound importance of receipt of SHH signals by the cilia in stromal reciprocity in PDAC. In other cancers, examples of potent roles for SHH and cilia-mediated stromal reciprocity include breast cancer, where an epithelial HH and/or stromal GLI1 signature predicted poor survival and increased metastasis 76 . SHH conditioning of stromal cells contributes to prostate cancer growth 77 ; IHH secreted by adenomatosis polyposis coli (Apc)-mutated colonic epithelia conditions gut stroma to support adenoma formation and growth in mice 78 . This appears to be a common mechanism for activating the TME.
Oncogenic signalling can cause loss and/or shortening of cilia. As noted above, the regulation of the primary cilium is closely associated with cell cycle, with greatest prevalence of the structure in quiescent postmitotic cells and most consistent loss occurring before mitosis 15, 68 . Over the past several decades, a question of high interest in the field of ciliary biology has been whether cilia qua cilia have an active role in restricting cell cycle re-entry and whether the structure intrinsically functions as a tumour suppressor. Although this topic has been much discussed, it has been difficult to resolve, as many proteins originally thought to be cilia-specific have emerged as having additional non-ciliary functions. However, evidence exists that defined driver oncogenes or transformation-associated processes that target the cell cycle also directly affect ciliation.
AURKA is a serine/threonine kinase that is most studied for its activity in mitosis and was first identified as an oncogenic driver of transformation and genomic instability for breast tumours and was subsequently shown to act as an oncogene in many other tumour types 18 . Building on work in Chlamydomonas 79 , transient activation of AURKA before resorption of ciliation was found to occur not only at the G2-M transition point, where AURKA activity was well documented, but also in quiescent G0-G1 cells in a pool of AURKA localized to the ciliary basal body. Such AURKA activation is a necessary and sufficient proximal driver of ciliary resorption for humans and other vertebrates in both cancer and untransformed cell types 68, 80 . AURKA activation requires interaction with a number of partner proteins; at least some of these proteins, such as neural precursor cell expressed, developmentally down-regulated protein 9 (NEDD9), were shown to be required for ciliary resorption 81 and are oncogenically overexpressed in a substantial number of tumour types in mice and humans 82 . Conversely, interactions of the von Hippel-Lindau disease tumour suppressor VHL and glycogen synthase greater ciliation of stromal cell populations, increasing paracellular SHH signalling but also creating an autocrine SHH signalling loop in tumours. In this case, the PI3K inhibitor, but not the AURKA inhibitor, will also limit the downstream consequences of the stromal-to-tumour signalling loop by targeting PI3K , which is downstream of insulin-like growth factor 1 (IGF1) and growth arrest-specific 6 (GAS6) and/or the AXL oncogene receptor tyrosine kinase, in cancer cells. A heat shock protein 90 (HSP90) inhibitor such as ganetespib may have complicated action, supporting general deciliation that eliminates both paracellular and autocrine cilia-mediated signalling, and may directly inhibit multiple signalling pathways within cancer. Consequences for other cell types within the cell mass, and for the extracellular matrix (ECM), are also likely based on known signalling relationships. CKs, chemokines and cytokines; VEGF, vascular endothelial growth factor.
volume 18 | AuGuST 2018 | 517 3β (GSK3β) are essential for ciliary maintenance. Loss of these proteins in mammalian kidney cells causes rapid ciliary loss, in part because VHL inactivation stabilizes the transcription factors hypoxiainducible factor 1 (HIF1) and/or HIF2 (reF.
83
) as well as β-catenin, thereby activating AURKA and NEDD9. Given the near ubiquity of VHL suppression in renal cell carcinomas (RCCs, a type of tumour that like many others is characterized by reduced ciliation), AURKA is active in this disease 84 . By contrast, induction of histone deacetylase 2 (HDAC2) contributes to elevated AURKA activity and loss of cilia in PDACs 85 .
Oncogenes that stimulate continuous proliferation and prevent cells from entering quiescence also decrease ciliation as an indirect consequence of the cells not entering a quiescent state. Oncogenically activated KRAS suppresses the programme of cilia formation through a process that is poorly defined but reversible in vitro by inhibition of the KRAS effector PI3K (reF.
60
).
This potent activity of RAS, coupled with the common nature of RAS mutations in many tumours, is likely to contribute to common loss of ciliation.
RAS is a central downstream effector of numerous RTKs, including EGFR, PDGFR, FGFR and others that are commonly amplified or have activating mutations in tumours. Some of the earliest studies of molecular controls of ciliary resorptionprotrusion cycles focused on the fact that ciliary protrusion required growth of cells under conditions of low or no serum, while serum induced rapid resorption. The first serum factor shown to specifically induce ciliary resorption was PDGF 86 ; EGF, IGF1 and FGF also contribute to resorption 87 . Overexpression and/or constitutive activation based on mutation of the RTKs for these growth factors would be expected to decrease ciliation. For example, activation of the EGFR kinase has been shown to suppress ciliogenesis in retinal pigmented epithelial cells 88 . It is also important to note that some of these receptors promote ciliary resorption even though they are not located at cilia (for example, PDGFRβ 89 ). Suggestively, genomic data of ciliadependent medulloblastoma and BCC cells show a paucity of genetic changes involving activated or overexpressed AURKA, VHL, RAS or RTK genes. For example, in 46 patients with medulloblastoma reported in The Cancer Genome Atlas (TCGA) 90 , and an additional 125 patients in an independent study 91 , no mutations affecting VHL, RAS or RTK genes were detected. In 293 specimens of BCC 92 , mutations affecting PTCH1 (in 74% of patients), SMO (in 20% of patients), suppressor of fused homologue (SUFU) (in 8% of patients), NOTCH1 (in 29% of patients) and NOTCH2 (in 26% of patients) were common, but no mutations or amplifications affecting RAS, VHL or AURKA were observed, with only 2% of patients having mutations in the RTK gene ERBB2. Nutrient limitation in rapidly growing tumours often triggers the pro-survival process of autophagy, involving the destruction and recycling of damaged proteins. Several studies have shown that activation of autophagy influences ciliogenesis 93 . Studies in the human breast cancer cell line MCF7 as well as in nonmalignant murine and human cell models indicated that induction of autophagy is associated with ciliary protrusion and lengthening, whereas inhibition of autophagy results in cilia shortening and loss 94, 95 . Reciprocally, on the basis of studies in multiple murine cell types, cilia-based signals from HH or other factors can activate proteins trafficked to the basal body by the IFT apparatus, with IFT-deficient cells having a reduced level of autophagy 96 . In cancer cells, specific oncogenic signals, rapid cell cycle progression and increased autophagy stimulate proteasomal activity. There are extensive connections between ciliation status, the ciliary transport machinery and regulation of the proteasome in normal and transformed cells (reviewed recently by reF.
97
). For example, studies in human primary cultures, murine tissues and zebrafish models indicate that ciliary proteins including BBS4 and oral-facialdigital syndrome 1 protein (OFD1) directly interact with subunits of the proteasome, supporting expression and activity of the proteasome at the ciliary base, and regulate the cancer-relevant nuclear factor-κB (NF-κB) pathway 98 . Also, proteasomal regulation of the ciliary protein trichoplein keratin filament-binding protein (TCHP), an AURKA inhibitor, influences ciliation in human retinal pigmented epithelial cells and other cell models 99 as well as the ability of cells to respond to signals emanating from ciliary receptors.
Ciliary proteins affect cancer initiation and progression. Although there has been little previous organized effort to connect changes in ciliation to cancer per se, a growing number of studies indicate a role of genes with roles in control of ciliary structure or function in carcinogenesis. Although it has not yet been established whether the functions of the respective genes in cilia are connected to or independent of their role in cancer, the number of examples suggests a direct link that deserves further investigation. For example, split ends (SPEN), an oestrogen receptor co-repressor, is co-expressed with a suite of ciliary genes and supports ciliary biogenesis. On the basis of small interfering RNA-mediated depletion experiments, SPEN promotes migration in the ciliated, immortalized but not transformed MCF-10A cell line and in ciliated, but not unciliated, human breast cancer cells; in addition, studies of patients with breast cancer found a correlation between early metastasis and high expression levels of SPEN in two independent cohorts of 77 (HR 2.25, P = 0.03) and 170 (HR 2.23, P = 0.004) patients. Interestingly, the correlation was observed in patients with hormone receptor (HR)-negative disease, which has cells with some ciliation, but not HR-positive breast cancer, which has cells that typically lack primary cilia 100 . NEK2 interacts with KIF24 to regulate cilia disassembly during the cell cycle. NEK2 was highly overexpressed (5-fold to 30-fold) in all members of a panel of breast cancer cell lines of various subtypes in comparison with normal human mammary epithelial cells. Depletion of NEK2 increased ciliation and supported proliferation in breast cancer cells that lack cilia, including the triple-negative Hs578T cell line model; function-testing experiments indicated that interactions between NEK2 and KIF24 are required for these activities 101 . Knockdown of the gene encoding tubulin monoglycylase (TTLL3), which modifies the ciliary axoneme, reduced the number of primary cilia and increased the proliferation of colon epithelial cells, strongly promoting the development of colorectal carcinomas (CRCs) in a mouse model. Decreased levels of TTLL3 were associated with progression of human CRC 102 . In a mouse model of SHH-dependent medulloblastoma with expression of constitutively active SMO, inositol polyphosphate 5-phosphatase (INPP5E) was required for proliferation, tumour progression and SHH signalling. In this model, INPP5E regulates a ciliacompartmentalized phosphatidylinositol-3,4,5-phosphate (PtdIns(3,4,5)P 3 )-AKT-GSK3β signalling axis to maintain tumour cell cilia. Interestingly, in a subset of human medulloblastomas, low INPP5E mRNA levels were associated with increased overall survival 103 .
The PCP effector inturned (INTU) is overexpressed in human BCC, with increased INTU expression correlating with elevated formation of primary cilia and HH pathway activity. On the basis of in vitro and in vivo experiments using a mouse model, Intu is essential for formation of primary cilia and HH signalling in BCC because of its role in promoting IFT complex A assembly 104 . Experiments in two in vitro cell lines used as models for cell polarity controls (MDCK and the moderately ciliated LNCaP prostate cancer cell line), supplemented by analysis of tissue development in Xenopus, demonstrated that hyperactivation of the lipogenic transcription factor sterol regulatory element-binding protein 1c (SREBP1c), which is associated with the abnormal activation of fatty acid synthesis pathways in many cancers, disrupted cilium formation and caused ciliary defects in environmental sensing. These defects were associated with distortion of polarized tissue structure. Conversely, blockade of SREBP1c-activating cleavage increased LNCaP cell ciliation fivefold 105 . The polarization defect seen with SREBP1c overexpression likely reflects the ciliary defect, given the other related findings linking ciliation status and integrity of polarized epithelial sheets 106 and the dense connections mapped out between IFT proteins and the ciliogenesis and planar polarity effector (CPLANE) complex 107 . Links between DNA damage response (DDR) and ciliary proteins are emerging 108 . For example, studies in two standard cell line models of ciliation (human RPE1 cells and mouse inner medullar collecting duct (IMCD3) cells) and a zebrafish in vivo model have shown that mutation or loss of the gene that encodes centrosomal protein of 164 kDa (CEP164) causes defects of ciliogenesis concomitant with defects in DDR, in addition to defects in EMT and changes in the rate of apoptosis 109 . NEK8, which is encoded by a gene that is mutated in the ciliopathy nephronophthisis, was identified as a critical component of the DDR linked to replication stress, on the basis of work using several human cancer cell lines and IMCD3 cells 110 .
In families with evidence of inherited testicular germ cell tumours, 8.7% bear damaging mutations in cilia-microtubule genes. Of these, disruption of dynein axonemal assembly factor 1 (DNAAF1) predominantly localized to the cilia, although it was also found at the spindle poles in some cell lines. This disruption is implicated in primary cell dyskinesia of motile cilia and in male infertility and the encoding gene is one of the most substantially mutated genes in these defects. Some of the other genes noted included dynein cytoplasmic 2 heavy chain 1 (DYNC2H1), dynein regulatory complex subunit 1 (DRC1) (which are both localized to the tubulin cytoskeleton and ciliary axoneme) and CEP290 (which is more broadly localized to cytoskeleton, microtubule-organizing centre, centrosomes and basal body) 111 . Transcription factors known to induce proteins involved in ciliary formation (including the regulatory factor X (RFX) factors and forkhead box protein J1 (FOXJ1)) are increasingly linked to roles in tumour formation and prognosis 112 . Whether these functions are linked or independent is a current topic of investigation.
An extensive study comparing patterns of mutation in spontaneous human RCC versus a murine RCC arising from triple mutation of Vhl, Trp53 and Rb1 showed similar enrichment for disruption of ciliary genes: 40% of human tumours analysed contained one or more such mutations 113 .
Owing to space limitations, this is an incomplete list of recent, in-depth ciliacancer studies, representing a rapidly growing field. In addition to those discussed above, high-throughput screens and database analyses have suggested further cilia-associated genes relevant to cancer biology (Supplementary Table 1 ).
Drug-cilia interactions
The oncogenic pathways described in the preceding section include some of the most studied and most druggable pathways in cancer therapy. Until recently, given the prevailing view that cilia were mostly relevant to ciliopathies and developmental signalling, little work explicitly addressed the hypothesis that some or many cancer drugs may be targeting cilia and that the activity of these drugs on cilia in the cancer cell or cells in the TME may influence signalling responses in potentially unpredictable ways. However, a growing number of publications support the idea that drug-cilia interactions in cancer are not uncommon (TaBle 1) .
Some of the earliest studies of flagella and cilia probed regulation of the protrusion-resorption cycle with taxanes and vinca alkaloids, agents that provide the basis for common chemotherapies. Given the importance of regulated IFT on a dynamic microtubule-based axoneme for this cycle -in experiments performed in diverse models including mammalian cell lines, and vertebrate and invertebrate organisms -it is unsurprising that some of these agents had potent effects, with the microtubule-destabilizing agents vinblastine and colcemid blocking ciliary formation [114] [115] [116] and taxol inducing elongated, morphologically abnormal cilia 117 . More recently, the role of cytoskeletal proteins and modifications in controlling the ciliary cycle and ciliary length has been probed by several groups, revealing dependence on actin, tubulin and associated proteins 118 . Among targeted agents, alisertib is a selective AURKA inhibitor under clinical development for relapsed and/ or refractory peripheral T cell lymphoma and other indications 119 . Alisertib 81 and the chemically distinct Aurora kinase inhibitor PHA-680632 (reF.
80
) completely block ciliary disassembly in normal and immortalized mammalian cells in vitro and in vivo. However, although cilia are constitutively retained in cells treated with alisertib, the drug may partially disrupt ciliary signalling on the basis of observed ciliary morphological abnormalities and a trafficking defect in the ciliary protein adenylyl cyclase 6 (ADCY6) in alisertib-treated cells 81 . PLK1 function is linked to that of AURKA, and activated PLK1 also induces rapid loss of ciliation 120, 121 . Because PLK1, like AURKA, is important for entry into mitosis, targeted agents such as volasertib are also in clinical trials 122 . The activity of these agents in regulation of cilia has never been assessed. However, we can speculate that at least one such agent, rigosertib, described as a dual PLK1-PI3K inhibitor, may stabilize cilia, given the reports of PI3K being essential for KRAS-induced deciliation 60 and the reports of deciliation induced by an INPP5E mutation 87, 123 . RTK inhibitors are some of the most common targeted inhibitors in cancer treatment. Given the role of EGF, PDGF, FGF and other ligands for RTKs in promoting ciliary resorption, small-molecule and, potentially, antibody inhibitors of these RTKs would be expected to promote greater levels of ciliation. Of the limited data available, inhibition of PDGFRα with a neutralizing antibody, or treatment with the PI3K inhibitor Ly294002, promoted ciliary stability in experiments using mouse embryo fibroblasts and in an in vivo mouse model with wild-type or null Inpp5e (reF.
87
). A screen of drugs to identify agents able to restore cilia to PDAC cells identified the EGFR inhibitor gefitinib and sirolimus (also known as rapamycin), an inhibitor of the EGFR-RAS effector mTOR, and these results were confirmed in multiple human cancer cell lines (representing pancreatic, kidney, breast and lung cancers) 124 .
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Heat shock protein 90 (HSP90) is a chaperone for a number of oncogenic proteins, and several HSP90 inhibitors have advanced to the clinic on the basis of the addiction of tumours to oncogenes dependent on HSP90 (reF.
125
). The HSP90 inhibitor ganetespib causes rapid and sustained ciliary loss in murine and human cell types in vivo and in vitro through a mechanism involving reduction in proteasomal function and stimulation of AURKA, and HSP90-dependent deciliation is blocked by alisertib 126 .
It is important to remember that patients with cancer are typically in late middle age or elderly, and often have comorbidities including hypertension, diabetes, obesity and/or cardiovascular disorders 127 . In addition, patients with cancer are likely to experience anxiety or depression, either as a pre-existing condition or related to their cancer diagnosis 128 . Treatments for some of these additional pathological conditions are already known to affect cancer progression 129 . Hence, comorbidity is worth considering in the context of a discussion of ciliation and cancer, as some of the signalling systems associated with these disorders involve ciliary-localized receptors and some of the drugs in clinical development or used to treat comorbidities are known or, likely, to influence ciliation in some systems. Relevant examples of cilia-affecting drugs include those targeting the GPCR melanin-concentrating hormone receptor 1 (MCHR1), with such preclinical compounds in development for treatment of obesity and depression 130 ; drugs targeting the dopamine receptor system, including reserpine, which is in use for hypertension [131] [132] [133] ; and some benzodiazepines, which are in use for anxiety 134 . Potential interaction of such agents with cilia in the TME is essentially a black box.
An elegant recent study provides evidence for the therapeutic relevance of tumour modulation of ciliation as a cause of drug resistance in some cancer settings. Drugs targeting SMO have been developed as a means of inhibiting SHH signalling, with sonidegib (also known as LDE225) 135 , saridegib (also known as IPI-926) 136 and vismodegib (also known as GDC-0449) 137 having been assessed in preclinical and clinical trials for BCC, medulloblastoma and other cancers 138 . As predicted, SMO-targeted inhibitors are active in medulloblastomas dependent on mutations in PTCH1 that require ciliary signalling but not in those associated with downstream activating mutations 139 . Inhibition of HH is also productive in BCC, where HH inhibitory agents are advancing in the clinic 137 . In a transposon screen to identify genes that are important for resistance of Ptch1 −/− medulloblastoma cells to SMO inhibitors, it was shown that, following treatment with sonidegib, mutations in ciliogenesis genes, including Ofd1 and others, reprogrammed cells to a low-level 'persister' state, which served as a reservoir for future aggressive outgrowth of resister clones. Importantly, analysis of data sets reporting genomic information for SMO-inhibitor-naive versus treated BCC identified a much higher level of mutations associated with loss of ciliation in patients who had been treated and a gene signature associated with loss of ciliation 140 . These results directly implicate control of ciliation with therapeutic resistance.
Conclusions
Understanding and manipulating asymmetric ciliary signalling in cancer cells and cells of the TME can potentially improve our understanding of cancer pathogenesis and the application of anticancer therapies. For example, the fact that a subset of cancer drugs regulate ciliary dynamics in addition to their primary anticipated mode of action has a number of implications. First, such drugs may induce unexpected off-target effects based on elimination, stabilization or modification of the ciliary platform for cancer-relevant signalling. Dose scheduling that takes some of these interactions into account may be one way to capitalize on desirable interactions or to minimize undesirable interactions. As a simple example, drugs that stabilize or lengthen cilia should not be coadministered with drugs that inhibit ciliary signalling proteins. Second, drugs affecting ciliary dynamics will act differently in tumours depending on several factors, including the degree of ciliation and the dependence on cilia-based signalling in the specific cell lineage from which the cancer cell arises. Drug action will also be influenced by the importance of cancer cell-stromal cell interactions in that tumour type. Third, multiple factors contribute to heterogeneity in solid tumours and complicate efforts to develop personalized treatment strategies, including, among others, clonal variation, epithelial versus mesenchymal differentiation status and degree of hypoxia and autophagy. Cancer cells in tumours are likely to include more ciliated or less ciliated regions. Fourth, it is likely that more drugs affect ciliation than is currently appreciated. For example, and although much more work remains to be done in validation and exploration of the underlying mechanism, a recent screen suggests that drugs ranging from antibiotics to hormones to antiinflammatory agents can induce ciliation, at least in some models 124 . These issues likely impact therapeutic response. For example, although SMO inhibitors are showing promise in BCC and medulloblastoma, clinical trials to date have shown no efficacy in pancreatic cancer 141 . At the simplest level, this may reflect an inability of the drug to effectively penetrate the tumour mass. However, inhibition of SHH and/or SMO does not affect the growth of pancreatic cancer cells 136, 142 owing to the deciliation of pancreatic cancer cells with KRAS mutations, leaving potent cell-autonomous, pro-growth pathways intact. Indeed, some studies using mouse models indicate that genetic changes inactivating the SHH pathway in fact lead to more aggressive, metastatic cancers by eliminating the tumour-constraining role of the desmoplastic stroma 143, 144 . This might oppose the antitumour effects of such an inhibitor by eliminating the ability of SHH-treated fibroblasts to secrete IGF1 and GAS6 (reF.
75
) (Fig. 4b) . Alternatively, the fact that vismodegib was administered in combination with gemcitabine in the trial 141 may have impacted its effectiveness, as gemcitabine would potentially influence ciliation by causing transient arrest in S phase, at which point many cilia had resorbed.
Other preclinical and clinical studies with SMO and/or SHH inhibitors combine these agents with microtubule modulators, including paclitaxel 145, 146 , and combinations with the depolymerizing agent mebendazole have been proposed 147, 148 . It is hard to predict how these drugs will interact in cancer cells and in stromal cells; thus, monitoring ciliary expression and functionality would be informative. It is interesting to speculate how an SMO inhibitor would interact with targeted inhibitors of proteins such as PI3K and AURKA, which enhance ciliation (Fig. 4b) . Furthermore, as mentioned before, ciliary proteins can affect the DDR 108 . Therefore, mutations affecting ciliary proteins could modify and amplify the effect of mutations that influence canonical DDR proteins, thus affecting tumour and stromal response to DNA-damaging therapies.
Among future topics of interest is the process by which cilia shed and receive extracellular vesicles (known as ciliary ectosomes); ectosomes secreted from the ciliary tip modulate signalling in other cells 149 and downregulate signalling from cilia 150 , and their secretion is coupled to ciliation 15 . The contribution of ciliary ectosomes to cancer is currently a major topic of investigation. Finally, intriguing recent studies raise the possibility that cilia or some of their protein constituents modulate immune system function and response to cancer immunotherapies. For example, the immunological synapse allows molecular communication between T cells and antigen-presenting cells, which is absolutely essential for antigen recognition and immune response 151 . Striking similarities exist between the machinery for cilia assembly and the machinery for the formation of the immunological synapse, with both of these processes requiring IFT proteins and centrosomal docking at the plasma membrane; there are even some hints that immune cells harbour the potential to form cilia 54, 152, 153 . Defects in IFT-related proteins within immune cells may be expected and in some cases have been shown to impair immune cell maturation and function 47 . Loss of the ciliary protein KIF7 in immature thymocytes resulted in defects in HH signalling, delayed their maturation to CD8 + cells and impaired their interaction with the thymic epithelium in a manner that reduced major histocompatibility complex (MHC) class II expression on the surface of the epithelial cells 154 . These intriguing advances, coupled with the rich biology discussed earlier, make it likely that we are only at the dawn of understanding the complex role of ciliation in cancer.
